Rock Springs Capital AZTA Position
ActiveRock Springs Capital increased their position in Azenta Inc. (AZTA) in Q4 2025, holding $18.9M worth of shares across 569,100 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds AZTA.
Short interest stands at 16.4% of float with 6.6 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
About Azenta Inc.
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Full company profile →Short Interest
16.4%
6.6 days to cover
Rock Springs Capital AZTA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 569,100 | +28,700 | $18.9M |
| Q3 2025 | Increased | 540,400 | +10,000 | $15.5M |
| Q2 2025 | Increased | 530,400 | +55,400 | $16.3M |
| Q1 2025 | Held | 475,000 | — | $16.5M |
| Q4 2024 | Decreased | 475,000 | -57,500 | $23.8M |
| Q3 2024 | Decreased | 532,500 | -163,500 | $25.8M |
| Q2 2024 | Increased | 696,000 | +1,250 | $36.6M |
| Q1 2024 | Increased | 694,750 | +187,250 | $41.9M |
| Q4 2023 | Increased | 507,500 | +30,000 | $33.1M |
| Q3 2023 | Increased | 477,500 | +7,600 | $24.0M |
| Q2 2023 | Increased | 469,900 | +38,700 | $21.9M |
| Q1 2023 | New | 431,200 | +431,200 | $19.2M |
Frequently Asked Questions
Does Rock Springs Capital own AZTA?
Yes. As of Q4 2025, Rock Springs Capital holds 569,100 shares of Azenta Inc. (AZTA) valued at $18.9M. This data comes from their SEC 13F filing.
How many hedge funds own AZTA?
2 specialist biotech hedge funds currently hold AZTA, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy AZTA?
Rock Springs Capital's position in AZTA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's AZTA position increasing or decreasing?
Rock Springs Capital increased their AZTA position in the most recent quarter, adding 28,700 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AZTACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →